[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351332-105":59,"doc-detail-351332-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","epigenetic-modulation-to-overcome-immune-suppression-in-pancreatic-cancer","Epigenetic modulation to overcome immune suppression in pancreatic cancer","","Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal malignancies due to a fibrotic, immunosuppressive tumor microenvironment that blocks drug delivery and limits immune-cell infiltration. Aberrant epigenetic regulation shapes these barriers by controlling transcriptional programs governing tumor–immune crosstalk, stromal remodeling, and immune evasion. This review integrates evidence on epigenetic mechanisms that suppress antigen presentation, maintain immunosuppressive populations, and increase immune-checkpoint signaling, while epigenetic therapies can restore immunogenicity, reprogram fibroblasts, and enhance cytotoxic T-cell infiltration.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/epigenetic-modulation-to-overcome-immune-suppression-in-pancreatic-cancer/351332/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/epigenetic-modulation-to-overcome-immune-suppression-in-pancreatic-cancer/351332.png","ImageObject",300,407,{"name":92,"@type":93},"\tCallum ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is PDAC particularly resistant to immune-based therapies?","Question",{"text":112,"@type":113},"PDAC is characterized by a highly fibrotic, immunosuppressive tumor microenvironment that restricts drug delivery and reduces immune-cell infiltration.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do epigenetic dysregulations contribute to immune suppression in PDAC?",{"text":117,"@type":113},"They control transcriptional programs that suppress antigen presentation, sustain immunosuppressive cell populations, and increase immune checkpoint molecules.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic strategies does the review highlight to improve PDAC immune responsiveness?",{"text":121,"@type":113},"It emphasizes combining epigenetic modulators with immune checkpoint blockade or targeted therapies to remodel the tumor microenvironment and convert immunologically 'cold' tumors into more responsive ones.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351332,1790125834,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","Drndakova et al. Clinical Epigenetics (2026) 18:49  \n[https://doi.org/10.1186/s13148-026-02081-5](https://doi.org/10.1186/s13148-026-02081-5)  \nClinical Epigenetics  \nREVIEW Open Access  \nEpigenetic modulation to overcome immune suppression in pancreatic cancer  \nLaura Drndakova 1†, Lucia Juhasikova1†, Ivana Hlavenova 1, Verona Buocikova 1, Sara Durdiakova2, Michal Mego2, Milan Buc3 and Bozena Smolkova1*  \nAbstract  \nPancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, primarily due to its highly fibrotic and immunosuppressive tumor microenvironment (TME), which limits both drug delivery and immune cell infiltration. Epigenetic dysregulation plays a pivotal role in shaping these barriers by controlling transcriptional programs that govern tumor-immune interactions, stromal remodeling, and immune evasion.  \nThis review synthesizes current insights into the contribution of aberrant epigenetic mechanisms to PDAC progression and immune resistance. We outline how epigenetic alterations suppress antigen presentation, sustain immunosuppressive cell populations, such as regulatory T cells, myeloid-derived suppressor cells, and tumorassociated macrophages, and upregulate immune checkpoint molecules across cancer and stromal compartments. Emerging evidence shows that epigenetic therapies targeting DNA methyltransferases, histone deacetylases, histone methyltransferases, or bromodomain proteins can restore tumor immunogenicity, reprogram cancerassociated fibroblasts, and promote cytotoxic T cell infiltration. Furthermore, combining epigenetic modulators with immune checkpoint blockade or targeted therapies has demonstrated the capacity to remodel the PDAC TME and convert immunologically ‘cold’ tumors into more responsive ones. Therefore, we also summarize key completed and ongoing clinical trials in PDAC and solid tumors, emphasizing outcomes and biomarker discoveries that support the translation of epigenetic-immunotherapy combinations into clinical practice. Finally, we discuss persistent challenges that impede progress, including poor drug penetration through the desmoplastic stroma, off-target effects and toxicity of epigenetic agents, tumor hypoxia, adaptive resistance, and the scarcity of physiologically relevant immuno-oncology models.  \nFindings from preclinical and early clinical studies indicate that epigenetic reprogramming represents a promising avenue to overcome PDAC immunoresistance by reactivating antigen presentation, disrupting immunosuppressive cellular networks, and enhancing antitumor immunity. However, realizing this potential will require rationally designed combination regimens, predictive biomarkers for patient stratification, and a deeper understanding of cell type-specific and context-dependent epigenetic regulation. Only through these advances  \n†Laura Drndakova and Lucia Juhasikova have contributed equally to this work and share first authorship.  \n*Correspondence:  \nBozena Smolkova [bozena.smolkova@savba.sk](bozena.smolkova@savba.sk)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, y","cbCaiswUAMzNc3rM","https://ap.wps.com/l/cbCaiswUAMzNc3rM","pdf",2327127,24,"English","# Abstract\n# Introduction\n# Findings from preclinical and early clinical studies\n# Clinical trials and translation challenges","[{\"question\":\"Why is PDAC particularly resistant to immune-based therapies?\",\"answer\":\"PDAC is characterized by a highly fibrotic, immunosuppressive tumor microenvironment that restricts drug delivery and reduces immune-cell infiltration.\"},{\"question\":\"How do epigenetic dysregulations contribute to immune suppression in PDAC?\",\"answer\":\"They control transcriptional programs that suppress antigen presentation, sustain immunosuppressive cell populations, and increase immune checkpoint molecules.\"},{\"question\":\"What therapeutic strategies does the review highlight to improve PDAC immune responsiveness?\",\"answer\":\"It emphasizes combining epigenetic modulators with immune checkpoint blockade or targeted therapies to remodel the tumor microenvironment and convert immunologically 'cold' tumors into more responsive ones.\"}]","Epigenetic modulation to overcome immune suppression in pancreatic cancer | PDF",1790093578,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa3cc06f860cf6d92279bbecd246d17d.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3a81f76c1bcacb73871dc341ba10d6d.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b72bd9c8d190d8fc02da8edb2a99268c.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20b528d716f9b76e3e50aea885943f2c.webp",980,1306]